Kevin Mclaughlin - Sep 23, 2021 Form 4 Insider Report for ACCELERON PHARMA INC (XLRN)

Role
SVP, CFO and Treasurer
Signature
/s/ Adam M. Veness, as attorney-in-fact for Kevin F. McLaughlin
Stock symbol
XLRN
Transactions as of
Sep 23, 2021
Transactions value $
-$3,011,252
Form type
4
Date filed
9/24/2021, 07:36 PM
Next filing
Nov 22, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XLRN Common Stock Options Exercise $75.4K +2.5K +23.41% $30.17* 13.2K Sep 23, 2021 Direct F1
transaction XLRN Common Stock Options Exercise $398K +9.8K +74.35% $40.61* 23K Sep 23, 2021 Direct F1
transaction XLRN Common Stock Options Exercise $305K +7.33K +31.9% $41.64* 30.3K Sep 23, 2021 Direct F1
transaction XLRN Common Stock Sale -$2.99M -18.6K -61.52% $160.26 11.7K Sep 23, 2021 Direct F1, F2
transaction XLRN Common Stock Sale -$159K -983 -8.43% $161.26 10.7K Sep 23, 2021 Direct F1, F3
transaction XLRN Common Stock Options Exercise $211K +5.2K +48.68% $40.61* 15.9K Sep 24, 2021 Direct F1
transaction XLRN Common Stock Options Exercise $7.08K +170 +1.07% $41.64* 16.1K Sep 24, 2021 Direct F1
transaction XLRN Common Stock Sale -$861K -5.37K -33.46% $160.38 10.7K Sep 24, 2021 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLRN Option to Purchase Common Stock Options Exercise $0 -2.5K -48.42% $0.00 2.66K Sep 23, 2021 Common Stock 2.5K $30.17 Direct F1, F5
transaction XLRN Option to Purchase Common Stock Options Exercise $0 -9.8K -37.32% $0.00 16.5K Sep 23, 2021 Common Stock 9.8K $40.61 Direct F1, F6
transaction XLRN Option to Purchase Common Stock Options Exercise $0 -7.33K -26.18% $0.00 20.7K Sep 23, 2021 Common Stock 7.33K $41.64 Direct F1, F7
transaction XLRN Option to Purchase Common Stock Options Exercise $0 -5.2K -31.59% $0.00 11.3K Sep 24, 2021 Common Stock 5.2K $40.61 Direct F1, F6
transaction XLRN Option to Purchase Common Stock Options Exercise $0 -170 -0.82% $0.00 20.5K Sep 24, 2021 Common Stock 170 $41.64 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.00 to $160.89 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.10 to $161.35 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.08 to $160.70 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
F5 The shares of common stock underlying this stock option award vested in equal quarterly installments over the four years after January 1, 2017.
F6 The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2018.
F7 The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2019.